Is Biogen’s Aducanumab Approvable? Opinions Divided Ahead Of Review
FDA Committee Meets On 6 November
Executive Summary
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.